144,100 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Louisiana State Employees Retirement System

Posted by Stanley Muller on Jun 28th, 2026

Louisiana State Employees Retirement System acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the 1st quarter, according to its most recent filing with the SEC. The fund acquired 144,100 shares of the company’s stock, valued at approximately $3,448,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Parallel Advisors LLC boosted its stake in shares of Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares during the last quarter. Lazard Asset Management LLC raised its stake in Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock valued at $1,631,000 after purchasing an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC raised its stake in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock valued at $2,516,000 after purchasing an additional 428 shares during the last quarter. Meeder Advisory Services Inc. lifted its holdings in Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after purchasing an additional 510 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its holdings in Elanco Animal Health by 4.2% in the 1st quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock valued at $342,000 after purchasing an additional 579 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Activity

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ELAN shares. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Citigroup raised their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, TD Cowen increased their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $28.55.

Read Our Latest Analysis on Elanco Animal Health

Elanco Animal Health Stock Up 0.8%

Shares of NYSE:ELAN opened at $24.56 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The business has a fifty day moving average of $23.04 and a two-hundred day moving average of $23.56. The stock has a market cap of $12.27 billion, a P/E ratio of -49.12, a PEG ratio of 1.61 and a beta of 1.69. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.